W
W

Wacker

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

CureVac may let contractors make rival vaccines if own shot fails -CEO

By Tilman Blasshofer and Ludwig Burger FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday. The German company saw billions of euros wiped
B
G
N
P
W

Novartis joins CureVac's vaccine contractor line-up

* Trial read-out expected early in second quarter * Other partners include Bayer, GSK, Fareva, Rentschler * Novartis site to come online in summer of 2021 * Novartis to make up to 50 mln doses this year By Ludwig Burger FRANKFURT, March 4 (Reuters) - German biotech firm CureVac 5CV.DE has enlisted Swiss pharmaceutical giant Novartis NOVN.S to help
B
G
N
W

Wacker Chemie: CitiGroup sees rebalancing of risks, cuts to "neutral"

** CitiGroup downgrades specialty chemicals maker Wacker Chemie WCHG.DE to "neutral" from "buy" saying sees a rebalancing of the risks as 2020 approaches ** The brokerage says that it sees 8.6% global supply growth in siloxane (silicones building block) driven by a wave of Chinese supply growth from established producers ** It says also sees risks
D
L
W

Aktia Bank, Kymmene Oyj, Wacker Chemie

Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Pirelli & C SpA, UPM-Kymmene Oyj and Wacker Chemie, on Thursday. HIGHLIGHTS * Aktia Bank Abp AKTIA.HE : Inderes raises to increase from reduce * Hembla AB HEMb.ST : Kepler Cheuvreux cuts to reduce from hold * Pirelli & C SpA PIRC.
A
A
C
C
D
D
E
E
E
E
G
K
L
O
R
S
W

Wacker Chemie Q3 adjusted EBITDA slumps due to falling silicon prices

Oct 24 (Reuters) - German chemicals company Wacker Chemie WCHG.DE reported a 34% drop in its third-quarter adjusted core profit, blaming lower silicon prices, inventory valuation adjustments and a supplier's plant shutdown. After adjusting for the effects of a one-off income from insurance compensation, Wacker posted its third-quarter earnings befo
D
L
W

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.